Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01754363




Registration number
NCT01754363
Ethics application status
Date submitted
18/12/2012
Date registered
21/12/2012
Date last updated
15/08/2024

Titles & IDs
Public title
Survivorship of Attune Primary Total Knee Prosthesis
Scientific title
Short, Medium and Long Term Survivorship of Attune Primary Knee Prosthesis
Secondary ID [1] 0 0
10008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Noninflammatory Degenerative Joint Disease 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Attune Primary Total Knee Replacement

Experimental: Attune Primary Total Knee Replacement - Subjects will receive one of the following Attune total knee implants:

Cruciate retaining fixed bearing (CR FB) Cruciate retaining rotating platform (CR RP) Posterior stabilized fixed bearing (PS FB) Posterior stabilized rotating platform (PS RP)


Treatment: Devices: Attune Primary Total Knee Replacement
Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Survivorship of each configuration.
Timepoint [1] 0 0
Minimum 15 years (5414 - 5658 days)
Secondary outcome [1] 0 0
Survivorship
Timepoint [1] 0 0
Minimum 5 years (1764 - 3588 days)
Secondary outcome [2] 0 0
Survivorship
Timepoint [2] 0 0
Minimum 10 years (3589 - 5413 days)
Secondary outcome [3] 0 0
Implant fixation: Radiographic assessment of bone-implant interface performance
Timepoint [3] 0 0
Minimum 1 year (304 - 668 days)
Secondary outcome [4] 0 0
Implant fixation: Radiographic assessment of bone-implant interface performance
Timepoint [4] 0 0
Minimum 2 years (669 - 1763 days)
Secondary outcome [5] 0 0
Implant fixation: Radiographic assessment of bone-implant interface performance
Timepoint [5] 0 0
Minimum 5 years (1764 - 3588 days)
Secondary outcome [6] 0 0
Implant fixation: Radiographic assessment of bone-implant interface performance
Timepoint [6] 0 0
Minimum 10 years (3589 - 5413 days)
Secondary outcome [7] 0 0
Implant fixation: Radiographic assessment of bone-implant interface performance
Timepoint [7] 0 0
Minimum 15 years (5414 - 5658 days)
Secondary outcome [8] 0 0
Patient Reported Outcome: EuroQol 5D 3L questionnaire (EQ-5D-3L)
Timepoint [8] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [9] 0 0
Patient-reported Outcome: Oxford Knee Score
Timepoint [9] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [10] 0 0
Patient-reported Outcome: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Timepoint [10] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [11] 0 0
Patient-reported Outcome: Pre-surgical/Post-surgical Patient's Knee Implant Performance (PKIP)
Timepoint [11] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [12] 0 0
Patient-reported Outcome: Knee Society Score
Timepoint [12] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [13] 0 0
Evaluate the impact of surgeon learning curve on clinical and functional outcomes
Timepoint [13] 0 0
<1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [14] 0 0
Evaluate changes in femoral component and tibial component alignment
Timepoint [14] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).
Secondary outcome [15] 0 0
Type and Frequency of Adverse Events (AEs) for all enrolled subjects
Timepoint [15] 0 0
Pre-op (-90 to -1 days before surgery), <1 year (1 - 303 days), minimum 1 year (304 - 668 days), minimum 2 years (669 - 1763 days), minimum 5 years (1764 - 3588 days), minimum 10 years (3589 - 5413 days), minimum 15 years (5414 - 5658 days).

Eligibility
Key inclusion criteria
* Subject is male or female and between the ages of 22 and 75 years at the time of surgery, inclusive.
* Subject was diagnosed with NIDJD.
* Subject is a suitable candidate for cemented primary total knee arthroplasty using the devices described in this protocol with either resurfaced or non-resurfaced patellae.
* Subject has given voluntary, written informed consent to participate in this clinical investigation and has authorized the transfer of his/her information to DePuy.
* Subject is currently not bedridden.
* Subject in the opinion of the Clinical Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedure and follow-up visits and co-operate with investigational procedures.
* Subject must be comfortable with speaking, reading and understanding questions and providing responses in an available translated language for the PROs in the protocol.
* The devices specified in this protocol were implanted.
Minimum age
22 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject is a woman who is pregnant or lactating.
* Contralateral knee has already been enrolled in this study.
* Subject had a contralateral amputation.
* Previous partial knee replacement (unilateral, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
* Subject is currently experiencing radicular pain from the spine.
* Subject has participated in an IDE/IND clinical investigation with an investigational product in the last three months.
* Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
* Subject is a known drug or alcohol abuser or has a psychological disorder that could affect their ability to complete patient reported questionnaires.
* Subject was diagnosed with fibromyalgia that is currently being treated with prescription medication.
* Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, Charcot disease).
* Subject is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, etc.).
* Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the protocol.
* Subject has a medical condition with less than 5 years of life expectancy.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2030
Actual
Sample size
Target
Accrual to date
Final
1542
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
Canberra Hospital-Trauma & Orthopaedic Research Unit - Adelaide
Recruitment postcode(s) [1] 0 0
ACT 2600 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Austria
State/province [11] 0 0
Lower Austria
Country [12] 0 0
Austria
State/province [12] 0 0
Upper Austria
Country [13] 0 0
Belgium
State/province [13] 0 0
Antwerp
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Germany
State/province [15] 0 0
Bavaria
Country [16] 0 0
Germany
State/province [16] 0 0
Heidelberg
Country [17] 0 0
Hong Kong
State/province [17] 0 0
Hong Kong
Country [18] 0 0
Korea, Republic of
State/province [18] 0 0
Dongjak-gu
Country [19] 0 0
Korea, Republic of
State/province [19] 0 0
Seoul
Country [20] 0 0
Malaysia
State/province [20] 0 0
Kuala Lumpur
Country [21] 0 0
New Zealand
State/province [21] 0 0
Auckland
Country [22] 0 0
Singapore
State/province [22] 0 0
Singapore
Country [23] 0 0
Switzerland
State/province [23] 0 0
Zurich
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Fife
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Scotland
Country [26] 0 0
United Kingdom
State/province [26] 0 0
Harlow
Country [27] 0 0
United Kingdom
State/province [27] 0 0
London
Country [28] 0 0
United Kingdom
State/province [28] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
DePuy International
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Allyson Morris
Address 0 0
DePuy Synthes
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01754363